ASX:RGS Regeneus (RGS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Regeneus Stock (ASX:RGS) 30 days 90 days 365 days Advanced Chart Get Regeneus alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume13,076 shsAverage VolumeN/AMarket CapitalizationA$3.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia. Read More Receive RGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneus and its competitors with MarketBeat's FREE daily newsletter. Email Address RGS Stock News HeadlinesCambium Bio Secures Ethics Approvals for Phase 3 Trials of Elate Ocular®June 29, 2025 | tipranks.comRegeneus Ltd. Announces Director Departure and Shareholding DetailsMay 22, 2025 | tipranks.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 9 at 2:00 AM | Crypto 101 Media (Ad)Cambium Bio Limited Appoints New Director to Strengthen LeadershipMay 22, 2025 | tipranks.comCambium Bio Gains FDA Approval for Elate Ocular® Phase 3 Trial AssayMarch 17, 2025 | tipranks.comCambium Bio Limited Aligns Leadership Interests with Share IssuanceMarch 12, 2025 | tipranks.comCambium Bio Limited Successfully Passes All Resolutions at General MeetingMarch 3, 2025 | tipranks.comCambium Bio Addresses Compliance OversightMarch 2, 2025 | tipranks.comSee More Headlines RGS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Regeneus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneus investors own include American Rebel (AREB), Pacific Biosciences of California (PACB), Docusign (DOCU), SuperCom (SPCB), Zion Oil & Gas (ZNOG), CASI Pharmaceuticals (CASI) and Carvana (CVNA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolASX:RGS CIKN/A Webregeneus.com.au Phone61 2 9499 8010FaxN/AEmployees630Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$1.69 million Net Margins-37.03% Pretax MarginN/A Return on Equity455.81% Return on Assets-62.56% Debt Debt-to-Equity Ratio-19.12 Current Ratio0.28 Quick Ratio0.46 Sales & Book Value Annual SalesA$1.02 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow21.67 Book ValueA($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares306,440,000Free FloatN/AMarket CapA$3.68 million OptionableNot Optionable Beta-0.24 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:RGS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneus Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.